David Hung
CEO
Nuvation Bio
Nuvation Bio is a late clinical-stage biopharmaceutical company developing novel therapies targeting difficult-to-treat cancers that have shown resistance to conventional treatments. Their approach focuses on creating differentiated product candidates that aim to improve patient outcomes by enhancing efficacy and reducing side effects.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$150MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many cancers develop resistance to existing therapies, and current treatments often have significant side effects, limiting their effectiveness and impacting patients' quality of life. There remains a significant unmet need for novel oncology medicines that can overcome drug resistance and improve patient outcomes in difficult-to-treat cancers.
Solution
Nuvation Bio is a biopharmaceutical company focused on developing differentiated and novel therapeutic candidates to address the most difficult-to-treat cancers. Their approach centers on creating oncology medicines that aim to improve patient outcomes by targeting mechanisms of drug resistance, enhancing efficacy, and reducing adverse effects compared to conventional therapies. Nuvation Bio is developing a deep pipeline of product candidates that target critical pathways cancer cells use to grow, with the goal of significantly improving outcomes over current standards of care.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers for whom conventional therapies have failed, as well as the physicians who treat them.
Features
- Focus on developing therapies for cancers that have shown resistance to conventional treatments.
- Pipeline of differentiated and novel therapeutic candidates.
- Aims to improve patient outcomes by enhancing efficacy and reducing side effects.
- Targets critical pathways that cancer cells use to grow.
- Clinical and preclinical studies demonstrate the potential to improve outcomes over current standards of care.